Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Genzyme Therapeutics
4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU
Telephone: +44 (0)1865 405 200
Fax: +44 (0)1865 774 172
WWW: http://www.genzyme.co.uk
Medical Information Direct Line: +44 (0)1483 505 515
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Customer Care direct line: +44 (0)1865 405 200
Medical Information Fax: +44(0)1483 554 805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 13/04/2011
PIL Fludara oral 10 mg film-coated tablet

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/04/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 11/11/2010 and displayed until 13/04/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 14/10/2010 and displayed until 11/11/2010
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • PIL Submitted in error
Updated on 14/12/2009 and displayed until 14/10/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to Marketing Authorisation Holder
Updated on 02/03/2009 and displayed until 14/12/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
Updated on 20/05/2008 and displayed until 02/03/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to Marketing Authorisation Holder
  • Company name change or merger
Updated on 03/04/2008 and displayed until 20/05/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 19/02/2008 and displayed until 03/04/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to information about pregnancy or lactation
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 19/07/2007 and displayed until 19/02/2008
Reasons for adding or updating:
  • Change to name of manufacturer
Updated on 20/12/2004 and displayed until 19/07/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 09/05/2002 and displayed until 20/12/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 13/02/2001 and displayed until 09/05/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  fludarabine phosphate